1. Scrip
  2. >>COVID-19

Coronavirus Update: Novavax Vaccine Listed By WHO, Filed In Japan

Plus, Booster OK For Moderna In Japan

 
• By Vibha Ravi and Ian Haydock

The WHO has granted an emergency listing to Novavax's COVID-19 vaccine, paving the way for wider use along with a new approval in the EU this week. The protein-based product has also just been filed in Japan, where Moderna's mRNA shot has been newly cleared for booster use.

Novavax vaccine
Novavax vaccine moves ahead globally • Source: Alamy

The World Health Organization (WHO) has granted an emergency use listing (EUL) to Serum Institute of India Pvt. Ltd.’s version of NVX-CoV2373, Novavax, Inc.'s recombinant nanoparticle protein-based COVID-19 vaccine, for immunization of individuals 18 years of age and older.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.